S100A8/A9 predicts triple-negative breast cancer response to PIM kinase and PD-1/PD-L1 inhibition

Lauren R. Begg(Northwestern University), Dai Horiuchi(Northwestern University)

bioRxiv (Cold Spring Harbor Laboratory)

September 23, 2023

10.1101/2023.09.21.558870

Cited by 1

Related Papers

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition

|The Journal of Experimental Medicine|2012|395

S100A8/A9 predicts response to PIM kinase and PD-1/PD-L1 inhibition in triple-negative breast cancer mouse models

|Communications Medicine|2024|7